安旭生物发预减，预计2025年年度归母净利润同比减少55.80%到63.08%

Core Viewpoint - Anxu Bio (688075.SH) forecasts a significant decline in net profit for the year 2025, projecting a net profit attributable to shareholders of between 71 million to 85 million yuan, representing a decrease of 107.30 million to 121.30 million yuan compared to the previous year, which translates to a year-on-year decline of 55.80% to 63.08% [1] Group 1 - The company's main business remains stable, indicating ongoing operational resilience despite the projected profit decline [1] - To strengthen its long-term competitive advantage in the industry, the company is maintaining the advancement of its existing technology platforms while strategically investing in new technology platforms [1] - Increased expenses are attributed to the expansion of domestic and international markets, as well as the establishment of overseas subsidiaries [1]